Holen Sie sich die Stockscreener-App
24.66
0.96%
-0.25
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Target Lowered | PCRX Stock News - GuruFocus
Where Pacira BioSciences Stands With Analysts - Benzinga
Pacira Q1 Adjusted Earnings Unchanged; Revenue Rises; 2025 Sales Guidance Steady - marketscreener.com
Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... - Yahoo
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences Reports Q1 2025 Financial Results - TipRanks
Pacer Advisors, Inc. Significantly Reduces Holdings in Pacira BioSciences Inc - GuruFocus
Pacer Advisors, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
Earnings call transcript: Pacira Q1 2025 shows revenue miss, stock dips - Investing.com India
Pacira BioSciences Inc Q1 2025 Earnings: EPS of $0.10 Misses Estimate, Revenue at $168.9 Million Below Forecast - GuruFocus
PCRX Reports Lower-Than-Expected Q1 Revenue, Focuses on Long-Term Strategy | PCRX Stock News - GuruFocus
Earnings Flash (PCRX) Pacira BioSciences Reports Q1 Adjusted EPS $0.62, vs. FactSet Est of $0.60 - marketscreener.com
Earnings Flash (PCRX) Pacira BioSciences Posts Q1 Revenue $168.9M, vs. FactSet Est of $176.0M - marketscreener.com
Pacira BioSciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Closing Strong: Pacira BioSciences Inc (PCRX) Ends at 25.15, Down -2.56 from Last Close - DWinneX
Preview: Pacira BioSciences's Earnings - Nasdaq
Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Pacira (PCRX) Reveals Promising Phase 1 Study Data for Gene Ther - GuruFocus
Pacira BioSciences to Present 3-Year Safety and Efficacy - GlobeNewswire
Revolutionary Gene Therapy Shows 3-Year Results for Knee Osteoarthritis: Pacira's PCRX-201 Data Revealed - Stock Titan
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - Louisiana First News
Pacira BioSciences soars 52% following InvestingPro’s October Fair Value alert By Investing.com - Investing.com
(PCRX) Trading Advice - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
How did Pacira BioSciences Inc (PCRX) fare last session? - uspostnews.com
Pacira BioSciences (PCRX) to Present Gene Therapy Study Results - GuruFocus
Pacira BioSciences (PCRX) to Present Gene Therapy Study Results | PCRX Stock News - GuruFocus
Pacira BioSciences to Present New Data on Clinical Immunogenicit - GuruFocus
Pacira BioSciences to Present Findings on PCRX-201 Gene Therapy for Knee Osteoarthritis at ASGCT 2025 - Nasdaq
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis - GlobeNewswire
Revolutionary Gene Therapy Data: Pacira's New Approach Could Transform Knee Osteoarthritis Treatment - Stock Titan
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $26.67 - Defense World
Are Smart Investors Making the Right Decision? Pacira BioSciences Inc (PCRX) - Sete News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
The Potential Rise in the Price of Pacira BioSciences Inc (PCRX) following insiders activity - knoxdaily.com
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for - Nasdaq
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - GlobeNewswire
Leading Pain Management Company Pacira Sets Q1 2025 Earnings Call DateKey Details Inside - Stock Titan
LPL Financial LLC Purchases Shares of 13,321 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences Inc (PCRX) Shares Up 3.97% on Apr 28 - GuruFocus
Pacira releases positive two-year data on knee osteoarthritis candidate - Seeking Alpha
Pacira BioSciences' Gene Therapy Shows Long-Term Improvement in Knee Osteoarthritis Symptoms - marketscreener.com
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee - GlobeNewswire
Invesco Ltd. Cuts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Zacks Research Issues Pessimistic Outlook for PCRX Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Pacira BioSciences Inc (NASDAQ:PCRX)’s 12-Month Price Target Currently Stands At 48 - Marketing Sentinel
Do investors need to be concerned about Pacira BioSciences Inc (PCRX)? - uspostnews.com
Pacira BioSciences Inc [PCRX] Officer makes an insider purchase of 500 shares worth 11625.0. - knoxdaily.com
Investors who hold shares of Pacira BioSciences, Inc. (NASDAQ: - openPR.com
Pacira BioSciences to Present 104-Week Efficacy Data - GlobeNewswire
0.00%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):